Generic vs Follow-On Peptide

Copying an approved peptide is not one route but three, and which applies depends on how the original was approved. A peptide regulated as a drug can be copied by an abbreviated new drug application, which requires the same active ingredient, route, form and strength plus bioequivalence and earns an Orange Book therapeutic equivalence code. A modified version goes through 505(b)(2) and is never automatically substitutable. A peptide regulated as a biologic is copied only as a biosimilar, with interchangeability decided separately.

Two structural events set the map. The 2020 transition under the Biologics Price Competition and Innovation Act moved insulin and human growth hormone to biologics licences, while peptides of forty or fewer amino acids stayed drugs. FDA then allowed abbreviated applications for highly purified synthetic peptides referencing recombinant listed drugs, naming glucagon, liraglutide, nesiritide, teriparatide and teduglutide, provided peptide-related impurities are characterised. That guidance has been revised, so the operative version should be read from FDA.

The consequence is that generic carries a specific promise. A therapeutically equivalent product is substituted at the counter without the prescriber; a biosimilar is not unless separately designated interchangeable, and a 505(b)(2) product never is. Which of the three arrives, rather than the chemistry, determines how fast prices move.

The misuse to watch is grey-market material advertised as generic semaglutide. No abbreviated application can be approved while the reference product's exclusivity and patents stand, so such material is not a generic in any regulatory sense. A related error assumes synthetic manufacture alone makes a peptide eligible for the abbreviated route, when eligibility turns on impurity comparability.